Tab: Quinine sulfate. Inj: Quinine dihydrochloride.
Injection: Each 2 ml contains Quinine Dihydrochloride 600 mg.
Pharmacology: Quinine is blood schizontocidal agent and is active against the asexual erythrocytic forms of Plasmodium falciparum, P. malariae, P. ovale, and P. vivax. The drug is not active against sporozoites or preerythrocytic or exoerythrocytic forms of plasmodia. Quinine is also gametocidal for P. malariae and P. vivax, but has no effect against the gametocyte of P. falciparum.
Quinine acts by interfering with the function of DNA, the oxygen uptake and the carbohydrate metabolism of plasmodium. The drug also has relaxant effect on skeletal muscle of plasmodium. It appears to increase the refractory period of the muscle by a direct action on the fiber, decrease the excitability of the motor endplate and affects the distribution of calcium within muscle fiber.
Tablet: P. falcifarum malaria resistant to chloroquine or other antimalarials.
Injection: Treatment of severe malarial infections in cases in which oral dosage form are not possible.
Tablet: Adult: 2 tab 8 hrly for 5-7 days. Children: 25 mg/kg 8 hrly for 5-7 days.
Injection: Adults: IV infusion, 600 mg, infused slowly over 1-hour period every 6-8 hours or 10 mg/kg body weight, infused slowly over a 4-hour period every 8-24 hours.
Children: IV infusion, 25 mg/kg body weight/day, divided into 2 doses every 6-8 hours. Each dosage should be infused slowly over 1-hour period.
Preparation of solution for IV infusion: Dilute each dose with 300 mL of 0.9% sodium chloride injection.
Tablet: In patients with G-6-PD defeciency, hypersensitivity to the drug, and in pregnant women.
Injection: Tinnitus or optic neuritis.
Use with caution in patients with artrial fibrilation, impairment of hearing, or visual disturbances, and in nursing woman.
Tablet: Serious heart disease, myasthenia gravis.
Injection: Caution is recommended when concomitantly use with other drugs such as neuromuscular blocking agents (pancuronium, succinylcholine, tubercurarine), digoxin, digitoxin, mefloquine, or quinidine.
Use in Pregnancy: It is contraindicated in pregnant women.
Use in Lactation: Use with caution in nursing woman.
Tinnitus, headache, nausea, disturbed vision, vomiting, abdominal pain, diarrhoea, vertigo, fever, pruritus, rash.
A syndrome known as cinchonism may occur in patients receiving high doses of quinine. Cinchonism is generally manifested by tinnitus, headache, nausea, and visual disturbances. Such effects usually disappear after discontinuation of the drug.
Hypersensitivity reactions including rash, fever, facial edema and dyspnea have been reported.
Store below 25°C. Protect from light.
P01BC01 - quinine ; Belongs to the class of methanolquinoline antimalarials.
Tab 300 mg x 1000's. Inj (amp) 600 mg/2 mL x 2 mL x 50 x 1's.